A Study Of PF-06263507 In Patients With Advanced Solid Tumors

Phase 1 Terminated 26 enrolled Pfizer

Open-labelTreatment

Summary

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Timeline

Start: 2013-08-08
Primary completion: 2015-06-29
Completion: 2015-06-29

Outcome

Outcome not reported

Stopped (Business): “The study was terminated on June 23, 2015 due to the company's change in prioritization for the portfolio and is not due to any safety concerns.”

Publications

Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, Shazer R, Taylor CT, Xuan D, Borghaei H. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):315-323. doi: 10.1007/s10637-016-0419-7. Epub 2017 Jan 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-06263507	Unknown	0.05 mg/kg	Intravenous
Subject	PF-06263507	Unknown	4.34 mg/kg	Intravenous
Subject	PF-06263507	Unknown	6.5 mg/kg	Intravenous